Przejdź do zawartości
Merck

M7824

Methotrexate

Synonim(y):

Methotrexate, (+)-Amethopterin, 4-Amino-10-methylfolic acid, 4-Amino-N10-methylpteroyl-L-glutamic acid, Antifolan, MTX, Methylaminopterin

Slide 1 of 1
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.

Wybierz wielkość

1 G

9140,00 zł

5 G

39 510,00 zł

9140,00 zł

Skontaktuj się z Obsługą Klienta, aby uzyskać informacje na temat dostępności
​
Zamów zamówienie zbiorcze

Informacje o tej pozycji

Wzór empiryczny (zapis Hilla):
C20H22N8O5
Numer CAS:
59-05-2
Masa cząsteczkowa:
454.44
EC Number:
200-413-8
UNSPSC Code:
41116107
NACRES:
NA.21
Beilstein/REAXYS Number:
70669
MDL number:
MFCD00064370

Kluczowe dokumenty

Wyświetl całą dokumentację

Przejdź do

Pomoc techniczna
Potrzebujesz pomocy? Nasz zespół doświadczonych naukowców chętnie Ci pomoże.
Pozwól nam pomóc

biological source

synthetic

Quality Level

400

form

powder

suitability

suitable for manufacturing use

storage temp.

−20°C

SMILES string

CN(Cc1cnc2nc(N)nc(N)c2n1)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1

InChI key

FBOZXECLQNJBKD-ZDUSSCGKSA-N

Gene Information

human ... DHFR(1719)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Porównaj podobne pozycje

Wyświetl pełne porównanie

Pokaż różnice

1 of 4

Ta pozycja
Y0001668Y0000602M9929
Methotrexate

SAFC

M7824

Methotrexate

Methotrexate for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001668

Methotrexate for system suitability

Methotrexate for peak identification European Pharmacopoeia (EP) Reference Standard

Y0000602

Methotrexate for peak identification

Methotrexate meets USP testing specifications

Sigma-Aldrich

M9929

Methotrexate

biological source

synthetic

biological source

-

biological source

-

biological source

synthetic

form

powder

form

-

form

-

form

powder

suitability

suitable for manufacturing use

suitability

-

suitability

-

suitability

-

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

−20°C

Quality Level

400

Quality Level

-

Quality Level

-

Quality Level

400

Gene Information

human ... DHFR(1719)

Gene Information

human ... DHFR(1719)

Gene Information

human ... DHFR(1719)

Gene Information

human ... DHFR(1719), DHFRP1(573971), FPGS(2356), SLC19A1(6573), TYMS(7298)
mouse ... Dhfr(13361)
rat ... Dhfr(24312)

General description

Inhibits thymidylate synthetase, is a nonselective de novo purine synthesis inhibitor and has a significant toxicity profile including hepatotoxicity, pneumonitis and bone marrow suppression. Potent folic acid antagonist. Induces apoptosis in HL-60 human leukemia cells. Also useful as an anti-tumor agent.
Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.

M-Clarity Program

Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.

Legal Information

SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany
Ta strona może zawierać tekst przetłumaczony maszynowo.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Muta. 2 - Repr. 1B - STOT RE 1

target_organs

Liver,Bone marrow

Klasa składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

flash_point_f

Not applicable

flash_point_c

Not applicable

Wybierz jedną z najnowszych wersji:

Certyfikaty analizy (CoA)

Lot/Batch Number
0000507508
0000507508
0000491173
0000502828
0000502828

Nie widzisz odpowiedniej wersji?

Jeśli potrzebujesz konkretnej wersji, możesz wyszukać konkretny certyfikat według numeru partii lub serii.

Wyszukaj dokument COA

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Christian S Kaas et al.
Biotechnology journal, 10(7), 1081-1089 (2015-05-13)
Coagulation factor VIII (FVIII) is one of the most complex biopharmaceuticals due to the large size, poor protein stability and extensive post-translational modifications. As a consequence, efficient production of FVIII in mammalian cells poses a major challenge, with typical yields
Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Axel Finckh et al.
Arthritis research & therapy, 16(5), 458-458 (2014-10-16)
Calcium pyrophosphate deposition (CPPD) may cause severe arthropathy, major joint destruction and treatment options are limited. The aim of this study was to test the therapeutic efficacy of methotrexate (MTX) in chronic or recurrent CPPD arthropathy. Patients with CPPD arthropathy
Anna-Birgitte Aga et al.
Annals of the rheumatic diseases, 74(2), 381-388 (2013-11-29)
To investigate whether baseline disease activity levels and responses in patients with rheumatoid arthritis (RA) changed during the period 2000-2010. Data were provided by the Norwegian disease-modifying antirheumatic drug (NOR-DMARD) study. Patients with inflammatory joint diseases starting new treatment with
Roy Fleischmann et al.
Annals of the rheumatic diseases, 74(6), 1132-1137 (2014-08-22)
Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) is used instead of erythrocyte sedimentation rate (DAS28-ESR) to assess rheumatoid arthritis disease activity; however, values for remission and low disease activity (LDA) for DAS28-CRP have not been validated.
Wyświetl wszystkie powiązane dokumenty

Numer pozycji handlu globalnego

SKUNUMER GTIN
M7824-5G04061832608563
M7824-1G04061826004821

Questions

Reviews

No rating value

Active Filters

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej